Published on Jun 03, 2020

  • Published on Jun 3, 2020
  • COVID-19 resulted in the rapid adoption of video visits and telemedicine.
  • Doctors say the acceleration of telemedicine  wouldn't have happened without a catastrophe or pandemic.
  • Technology has facilitated a rapid exchange of information, which has been both helpful and harmful. 

Video Transcript

JOHN WHYTE: You're watching Coronavirus in Context. I'm Dr. John Whyte, chief medical officer at WebMD. Today we're going to talk about how COVID is changing the practice of medicine. And I'm joined by Dr. Bob Harrington the chair of the Department of medicine at Stanford and Bob Brisco, the CEO of Internet Brands and WebMD. Gentlemen, thanks for joining me.

ROBERT HARRINGTON: Thanks for having me.

JOHN WHYTE: Dr. Harrington, COVID-19 certainly has had a tremendous impact on the practice of medicine. How do you see COVID changing your practice?

ROBERT HARRINGTON: Well, certainly here at Stanford, It changed a lot, and it changed it really quickly. Probably the most notable example of how it changed was the rapid movement to telemedicine. We were practiced that across the system was maybe making a couple of low percentage of video visits a day. Fast forward to about a month ago at the peak, we were doing almost 80% video visits across the practice.

Over the last couple of weeks, as we've begun to reopen the ambulatory practices, you can see us increasing the number of face-to-face visits, but we're still over 60% tele-visits, mostly video. And I think that that acceleration was something that probably wouldn't have happened without a catastrophe like the pandemic. So in some ways, that's a little bit of a silver lining, something that was long needed is now-- really was forced upon us. And I think we adapted as a-- as a community pretty quickly.

BOB BRISCO: Bob, is it too early to know where that percentage lands, ultimately? Do you think it settles back a certain rate, or--

ROBERT HARRINGTON: Yeah, we're-- we've been looking across the practice. If you look at the entirety of Stanford Medicine, we have about 600 separate clinics across our network, across our faculty practice for both the adults and the pediatric side. And we're estimating that in some of the groups, primary care for example, it might end up pretty high, maybe as much as 70%, 80%. Other practices, say oncology, a lot lower. When I talk to my oncology faculty during the past month, they were in the clinic seeing patients because they needed to do imaging. They needed to get physical examinations. They needed to start people on therapy.

In my practice-- I just ran over here from my own clinic today-- first three or four people I saw was via video then saw a couple of new patients. It's-- and I think that for the next foreseeable future of months, it'll probably be, in our in our particular practice-- I do mainly general cardiology these days-- maybe 50%, 60% video visits, a lot of follow-up for things like secondary prevention and more face-to-face visits for things like evaluation and heart failure, evaluation of valvular heart disease. I think it's going to depend on the specialty, Bob.

JOHN WHYTE: And Dr. Harrington, you're a teaching hospital. Part of your mission is educating students and residents. How does telemedicine impact their training?

ROBERT HARRINGTON: Yeah, it's a great question. First, in the inpatient area, that when we started surging up, it was really the residents who were trying to make sure the teams have residents, that they have fellows, that they have attending staff in some way because, as you know, that allows us to extend the reach of an attending. An attending can see third patients if he or she has a couple of residents to do a lot of the early groundwork, if you will. So that piece I think was really dependent upon the resident.

In the clinics, it's a little tougher with telemedicine. We're beginning to explore things like breakout rooms. There are some programs where my fellow, for example, can go into the-- can go into a room, see the patient, patient can then get passed over to another room, and I can see them. In my own clinic today, as I mentioned, I was there with one of our cardiology fellows who's been with me for the last few years. He's a very-- he's a senior fellow, very capable. He goes in, sees the patient on video, comes out and talks to me for a few minutes, and I go right back in to that exam room and see the patient via video. So I think we've had to adapt. I think that there are some innovative learnings.

BOB BRISCO: That brings us a little bit to the education topic. You're starting to get to it there. How do you see that changing?

ROBERT HARRINGTON: I think there's going to be opportunity to expand how many people we reach. We have a great example this summer. We've just received word from the-- the match program for residents that they do not want any face-to-face live interview visits over this coming interview season for internship. And so we're going to do the-- we're going to do all of our interviews for-- for residency here across the country, including here at Stanford, via Zoom technology and other technology.

I think that's a great opportunity to kind of show off some of the innovation that's going on at Stanford. I also think, frankly, it's a great opportunity to maybe reach some students who would like to take a look at Stanford but maybe they can't afford to fly around the country going to different places. Maybe, for whatever reason, they couldn't get the time off, maybe family obligations, et cetera.

I'm actually excited about the opportunity to maybe see a more diverse group of students apply to our residency program, which I think would be beneficial for us and might level the playing field a bit, that-- that students who wouldn't ordinarily have a chance to come here on an elective rotation can now be with us virtually and we can interview them. And boy, I'm really hopeful that we're going to see some students and maybe land some interns that we wouldn't have otherwise done.

JOHN WHYTE: Well, though, as you know, Dr. Harrington, some folks who are watching will say that they don't get to have those informal conversations with current residents or current students and get a real feel for what it's like.


JOHN WHYTE: See, I'm old and being old school. But I guess it's that balance while still trying to respond to really a new normal.

ROBERT HARRINGTON: I completely agree with you. I mean, one of the hallmarks of our residency interview days, the night before we host a reception and a dinner largely attended by our residents to meet with prospective interns. And I do think you're right. That's where you get the best feel of a program. We're having a lot of internal discussions now, how do we recreate some of that? How do we recreate that opportunity to have a little bit more of that informal network? And it's not-- it's definitely not as good as visiting. But how might we be able to add some things via technology that will get them excited about maybe the kind of things we have to offer here.

It is a bit of the new norm. I'm hopeful that over the long run, the new norm is a bit of a hybrid, that-- it's hard to replace-- it's funny, I was talking with my patients this morning. I said, I really-- I'm a social person. I miss seeing patients in the exam room and talking to them and just hanging out for a few minutes to hearing how they're doing. And I do miss that. Video doesn't replace that.

BOB BRISCO: You mentioned that COVID has accelerated the adoption of telemedicine. What else do you see that is catalyzed? Are clinical trials different now? Are there-- are there other things you could talk about that you think have been transformed because of necessity right now?

ROBERT HARRINGTON: Yeah, I think the communication of science has accelerated. And there's been both good and bad features of that-- maybe not bad, maybe challenging features of that. I read somewhere over the weekend that there's been something like 10,000 scientific articles, viewpoints, original research, observations put forward over the last couple of months that just really-- that's an explosion of science.

Now, a lot of that is good. A lot of that rapid exchange of information is really helpful. You know, what did we learn from the folks in China that we could take advantage of here in the US before it hit us? What did we learn from our colleagues in Boston and New York who were harder hit than we were here in California, and that rapid exchange of information is fantastic and facilitated by technology. Some of the bad things are that a lot of bad research got out there into the public sphere and was roundly criticized quickly by the peer review of Twitter and other social media indicators.

JOHN WHYTE: Well, you know, national meetings have always been a big part of your communication strategy. You've always been very popular at national meetings. With the cancellation of national meetings, how are you getting that education to your colleagues? How are you, you know, getting the information out?

ROBERT HARRINGTON: I happen to be president of the Heart Association this year, and so the last big meeting I went to was the scientific sessions in November. And then in this part of the year, there's a lot of what we call our specialty meetings. There's our Quality Cardiovascular Outcomes Research meeting, our Vascular Discovery meeting. There's a lot of meetings-- are epidemiology meeting was the last one I actually attended live back in February in Arizona, and this was sort of at the beginning of things where, you know, the hotel had sanitizer everywhere. We had moved from handshaking to what we called the epidemiology elbow bump to greet our colleagues. That was the last time we did a face-to-face meeting.

Now what I do is just what we're doing here. For each of the AHA smaller meetings, I've been recording my presidential address, and then I join the leadership of the meetings online to have some conversation. I've participated in some panels, things like that. We're, you know, planning Scientific Sessions in November now as a potential hybrid, where they will maybe be some people on site in Dallas and some people, maybe the majority, watching virtually. We don't know where that's going to fall out yet.

We know the European Society of Cardiology this summer has moved to complete virtual. That's the world's largest cardiovascular meeting. How's that going to be-- you know, how is that going to be received? 30,000 plus people typically attend that. So yeah, I-- there's-- there's things I miss. I don't miss being on planes. I don't miss being in hotel rooms. But I do miss seeing colleagues and friends from around the globe to do that informal networking, to learn from them, to talk about new things in science, et cetera.

BOB BRISCO: Bob, as you know, we work very closely with the largest pharmaceutical manufacturers. Do you have thoughts or advice for them and how they approach interacting with HCPs in a post-COVID basis?

ROBERT HARRINGTON: Oh, I think that post-COVID, we're going to spend a lot of time trying to figure out the optimal ways to-- to deliver education. I think it is going to be some hybrid of face to face and virtual. But I hope that we take some lessons learned from these virtual experience, and I'll give you a couple of examples that I think have been pretty good.

The chat function on-- on the virtual meetings has really opened up to people who might not otherwise ask questions. We now do our medical grand rounds virtually, and this is a-- grand rounds, you know, typical medical grand rounds, you both have been to more of these than you probably care to admit. And they are, you know, 150, 200 people on a busy day. We're getting upwards of 2,000 people coming to our medical grand rounds. And now we've developed a format where we get a lot of people participating as panelists who are answering the questions that are coming in during chat so then we can reserve the open forum for the really hot questions-- you know, what are the ones in voting that rise to the top?

So I think that there has been people speaking who wouldn't otherwise speak, who are asking questions who might have been reticent to do so. And I think we're getting a lot of great engagement. We don't want to lose this. When we go back to having our face to face, how do we make sure we don't lose the participatory, the engagement piece?

And so I would ask our friends who do a lot of sponsorship of educational events, what are they trying to achieve, and how can we work together to get great engagement, to communicate science? But also I think and what I've learned throughout this is that people want to discuss science. They just don't want to hear it.

They want to discuss it. They want to hear what you think, what John thinks, what I think, and then they want to discuss it with us, not just see three more PowerPoint slides. So that's something I think we all talk about, but this has really forced us to do it. BOB BRISCO: That's how people really learn, isn't it?


JOHN WHYTE: I want to thank you both for joining me.

ROBERT HARRINGTON: Thank you for having me.

JOHN WHYTE: And thank you for watching Coronavirus in Context.